MINNEAPOLIS, April 27, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD), a Bio-Techne brand, RNAscope⢠technology with release of new DNAscope Assays. The RNAscope technology is an advanced
in situ hybridization (ISH) assay that enables visualization of single-molecule gene expression with single-cell resolution directly in intact cells and tissues.
Bio-Techne's new chromogenic DNA
in situ hybridization (ISH) technology, DNAscope, employs the proven "double-Z" probe design and signal amplification system of RNAscope, enabling rapid and flexible probe development for any DNA target, enabling visualization of targets in formalin-fixed paraffin-embedded (FFPE) tissues. DNAscope delivers benefits over current commercial FISH techniques that fall short on morphological detail due to the use of fluorescent nuclear staining and rely on high-resolution microscopes to visualize gene rearrangement and copy number variation signals. Additionally, traditional FISH uses Bacterial Artificial Chromosome (BAC) clone-based probes that are large and tend to span multiple genes and lack single gene detection specificity which limits the scale and development of DNA research.